Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Public ClinicalTrials.gov record NCT07388524. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Evaluating Adjuvant Atezolizumab or Atezolizumab and Hyaluronidase-TQJS to Prevent Recurrence in Stage I Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase III Trial (AASI-NSCLC)
Study identification
- NCT ID
- NCT07388524
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Enrollment
- 336 participants
Conditions and interventions
Conditions
Interventions
- Atezolizumab Biological
- Atezolizumab and Recombinant Human Hyaluronidase Biological
- Biospecimen Collection Procedure
- Computed Tomography Procedure
- Patient Observation Other
Biological · Procedure · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 1, 2027
- Primary completion
- Sep 29, 2032
- Completion
- Sep 29, 2032
- Last update posted
- Jul 21, 2026
2027 – 2032
United States locations
- U.S. sites
- 14
- U.S. states
- 5
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Medical Oncology Hematology Consultants PA | Newark | Delaware | 19713 | Recruiting |
| Kootenai Health - Coeur d'Alene | Coeur d'Alene | Idaho | 83814 | Recruiting |
| Kootenai Clinic Cancer Services - Post Falls | Post Falls | Idaho | 83854 | Recruiting |
| Kootenai Clinic Cancer Services - Sandpoint | Sandpoint | Idaho | 83864 | Recruiting |
| Southern Illinois University School of Medicine | Springfield | Illinois | 62702 | Recruiting |
| Mary Greeley Medical Center | Ames | Iowa | 50010 | Recruiting |
| McFarland Clinic - Ames | Ames | Iowa | 50010 | Recruiting |
| Mercy Hospital | Cedar Rapids | Iowa | 52403 | Recruiting |
| Oncology Associates at Mercy Medical Center | Cedar Rapids | Iowa | 52403 | Recruiting |
| McFarland Clinic - Trinity Cancer Center | Fort Dodge | Iowa | 50501 | Recruiting |
| McFarland Clinic - Marshalltown | Marshalltown | Iowa | 50158 | Recruiting |
| Bozeman Health Deaconess Hospital | Bozeman | Montana | 59715 | Recruiting |
| Benefis Sletten Cancer Institute | Great Falls | Montana | 59405 | Recruiting |
| Community Medical Center | Missoula | Montana | 59804 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07388524, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 21, 2026 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07388524 live on ClinicalTrials.gov.